Politics Rachel Cohrs STAT Plus: Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use
Politics Rachel Cohrs STAT Plus: In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk
Politics Rachel Cohrs In a massive victory for Democrats, Medicare is poised to negotiate drug prices
Politics Rachel Cohrs STAT Plus: Democrats dramatically narrow their ambitions for lowering insulin costs
Politics Rachel Cohrs STAT Plus: Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules
Politics Rachel Cohrs STAT Plus: Drugmakers will be penalized if they hike prices on patients in private insurance market
Exclusive Rachel Cohrs STAT Plus: Medicare tasks a senior adviser with staffing its new drug pricing division
Exclusive Rachel Cohrs STAT Plus: Medicare lays out the bureaucracy it will need to negotiate drug prices
Matt's Take Matthew Herper STAT Plus: The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences
D.C. Diagnosis Rachel Cohrs The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill
Politics Rachel Cohrs STAT Plus: ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing
Politics Nicholas Florko STAT Plus: Powerful Senate Democrat outlines ‘plenty’ more drug pricing reforms to follow Medicare negotiation
Politics Alan Fram — Associated Press STAT Plus: Biden tells Dems to quickly pass pared-down economic package
Politics Rachel Cohrs STAT Plus: Democrats tweak their drug pricing plan in last-ditch effort to pass reforms
Politics Nicholas Florko STAT Plus: Three years after the Senate grilled drugmakers … nothing’s changed
Politics Rachel Cohrs STAT Plus: Insulin giants Eli Lilly and Novo Nordisk boosted their lobbying spending as Democrats eyed pricing reform
D.C. Diagnosis Nicholas Florko What does the Build Back Better Act actually mean for the health care industry?
Exclusive Rachel Cohrs How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal
Politics Rachel Cohrs STAT Plus: Here’s who wins and loses in Democrats’ new prescription drug pricing deal
Politics Lev Facher and Rachel Cohrs STAT Plus: Democrats circulate a new drug pricing outline with a big carveout for small biotechs
Politics Nicholas Florko and Rachel Cohrs STAT Plus: Here’s where Democrats’ resurrected drug pricing talks are headed
Politics Lev Facher STAT Plus: Here’s how Biden can address high drug prices, without help from Congress
Politics Rachel Cohrs STAT Plus: Pelosi working to gather support for last-minute, last-ditch drug pricing policy
Politics Rachel Cohrs STAT Plus: The four senators who could make or break Democrats’ drug pricing ambitions
Politics Nicholas Florko STAT Plus: Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs
Exclusive Rachel Cohrs and Nicholas Florko STAT Plus: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
Politics Rachel Cohrs and Nicholas Florko STAT Plus: In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking
Politics Rachel Cohrs STAT Plus: Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?